Response to Comments: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)

This article is a Response to Comments regarding the Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) Local Coverage Determination (LCD L40056), summarizing comments received by Noridian, CGS, National Government Services, and Palmetto GBA during the open comment period. It provides administrative dates (comment period described as beginning 2/67/25 and ending 3/22/25, notice period beginning 9/11/25, and effective date 10/26/25) and does not itself state specific clinical coverage, limitation, documentation, or frequency criteria.